Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

NCT03201757 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT03201757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03201757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 15, 2017
Completion date
September 6, 2023
Enrollment
523 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizophrenia, schizophreniform disorder